Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Combination Therapy for the Clinical Management of Hypertension

  • Chapter
Pathophysiology and Pharmacotherapy of Cardiovascular Disease

  • 4298 Accesses

Abstract

Effective treatment of hypertension represents a key strategy for preventing major cardiovascular events, including myocardial infarction, stroke, congestive heart failure and cardiovascular death. In spite of these well-established concepts, hypertension remains poorly controlled, worldwide. To reduce this gap and to improve blood pressure control at general population level, the use of rational, synergistic and integrated pharmacological strategies have been proposed over the last few years. Indeed, a more extensive use of dual or triple combination therapy, particularly in fixed formulation, is progressively emerging as a cornerstone of a more effective treatment of hypertension in clinical practice. Among different combination therapies currently available for the clinical management of hypertension, those based on the association of drugs inhibiting the renin-angiotensin system, renal tubular reabsorption of electrolytes and transmembrane influx of calcium ions, both in dual- and in triple-fixed combination formulations, have been demonstrated to be very effective in lowering both systolic and diastolic, clinic as well as 24-h ambulatory blood pressure levels with a good tolerability and safety profile. In the present chapter, we provide a systematic and updated overview of the evidence supporting the use of combination therapies with different classes of antihypertensive drugs, with a particular focus on those based on drugs inhibiting the renin-angiotensin system (e.g. angiotensin-converting enzyme inhibitors, angiotensin AT1 receptor blockers), reabsorption of sodium chloride and water (e.g. thiazide diuretics) and calcium channels (e.g. amlodipine). In addition, we review the currently available clinical data addressing the effects of combination therapies on adherence and persistence on prescribed antihypertensive medications compared to monotherapies, as well as safety and tolerability profile of such different treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tocci G, Sciarretta S, Facciolo C, Volpe M. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Rev Cardiovasc Ther. 2007;5(4):767–76. doi:10.1586/14779072.5.4.767.

    Article  CAS  PubMed  Google Scholar 

  2. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410–9. doi:10.1001/archinte.165.12.1410. 165/12/1410 [pii].

    Article  PubMed  Google Scholar 

  3. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35. S0140673603147393 [pii].

    Article  CAS  PubMed  Google Scholar 

  4. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336(7653):1121–3. doi:10.1136/bmj.39548.738368.BE. bmj.39548.738368.BE [pii].

    Article  CAS  PubMed  Google Scholar 

  5. Williams B. The year in hypertension. J Am Coll Cardiol. 2009;55(1):65–73. doi:10.1016/j.jacc.2009.08.037. S0735-1097(09)03377-4 [pii].

    Article  PubMed  Google Scholar 

  6. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929–40. doi:10.1016/S0140-6736(09)60330-5. S0140-6736(09)60330-5 [pii].

    Article  PubMed  Google Scholar 

  7. Whyte JL, Lapuerta P, L’Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988–1994. J Clin Hypertens (Greenwich). 2001;3(4):211–6.

    Article  CAS  Google Scholar 

  8. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10–7. doi:10.1161/01.HYP.0000103630.72812.10. 01.HYP.0000103630.72812.10 [pii].

    Article  CAS  PubMed  Google Scholar 

  9. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377(9765):568–77. doi:10.1016/S0140-6736(10)62036-3. S0140-6736(10)62036-3 [pii].

    Article  PubMed  Google Scholar 

  10. Bramlage P, Bohm M, Volpe M, Khan BV, Paar WD, Tebbe U, et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich). 2010;12(9):666–77. doi:10.1111/j.1751-7176.2010.00322.x.

    Article  Google Scholar 

  11. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18(6):308–47. doi:10.3109/08037050903450468.

    Article  CAS  PubMed  Google Scholar 

  12. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. doi:10.1093/eurheartj/eht151.

    Article  PubMed  Google Scholar 

  13. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. doi:10.1001/jama.2013.284427.

    Article  CAS  PubMed  Google Scholar 

  14. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407. doi:10.1161/HYPERTENSIONAHA.109.139816. HYPERTENSIONAHA.109.139816 [pii].

    Article  CAS  PubMed  Google Scholar 

  15. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28(7):1584–90. doi:10.1097/HJH.0b013e328339f9fa.

    Article  CAS  PubMed  Google Scholar 

  16. Volpe M, Rosei EA, Ambrosioni E, Cottone S, Cuspidi C, Borghi C, et al. 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global cardiovascular risk stratification to combination therapy. High Blood Press Cardiovasc Prev. 2013;20(1):45–52. doi:10.1007/s40292-013-0007-2.

    Article  CAS  PubMed  Google Scholar 

  17. O’Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31(9):1731–68. doi:10.1097/HJH.0b013e328363e964.

    PubMed  Google Scholar 

  18. Volpe M, Tocci G. Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice. Expert Rev Cardiovasc Ther. 2010;8(6):811–20. doi:10.1586/erc.10.47.

    Article  PubMed  Google Scholar 

  19. Volpe M, Tocci G. Managing hypertension in cardiology practice according to risk profile. Int J Clin Pract. 2008;62(9):1403–12. doi:10.1111/j.1742-1241.2008.01821.x. IJCP1821 [pii].

    Article  CAS  PubMed  Google Scholar 

  20. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26(4):819–24. doi:10.1097/HJH.0b013e3282f4edd7. 00004872-200804000-00030 [pii].

    Article  CAS  PubMed  Google Scholar 

  21. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25(5):951–8. doi:10.1097/HJH.0b013e3280bad9b4. 00004872-200705000-00010 [pii].

    Article  CAS  PubMed  Google Scholar 

  22. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906. doi:10.1016/S0140-6736(05)67185-1. S0140-6736(05)67185-1 [pii].

    Article  PubMed  Google Scholar 

  23. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97. joc21962 [pii].

    Article  Google Scholar 

  24. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28. doi:10.1056/NEJMoa0806182. 359/23/2417 [pii].

    Article  CAS  PubMed  Google Scholar 

  25. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290–300. doi:10.1016/j.amjmed.2008.09.038. S0002-9343(08)00992-3 [pii].

    Article  PubMed  Google Scholar 

  26. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427. doi:10.1136/bmj.326.7404.1427. 326/7404/1427 [pii].

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069–75. doi:10.1161/HYPERTENSIONAHA.111.169961. HYPERTENSIONAHA.111.169961 [pii].

    Article  CAS  PubMed  Google Scholar 

  28. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839–45. doi:10.1161/01.HYP.0000259805.18468.8c. 01.HYP.0000259805.18468.8c [pii].

    Article  CAS  PubMed  Google Scholar 

  29. Anschutz F, Burkert E. The errors in auscultatory measurement of the blood pressure according to Riva-Rocci/Korotkoff on extensive soft parts. Z Kreislaufforsch. 1954;43((9-10):335–43.

    CAS  PubMed  Google Scholar 

  30. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–13. doi:10.1056/NEJMoa1208799.

    Article  CAS  PubMed  Google Scholar 

  31. Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125–35. doi:10.1001/jama.2013.1954.

    Article  CAS  PubMed  Google Scholar 

  32. Volpe M, Tocci G, Bianchini F, De Rosa M, Fedozzi E, Covezzoli A, et al. Use of aliskiren in a ‘real-life’ model of hypertension management: analysis of national Web-based drug-monitoring system in Italy. J Hypertens. 2012;30(1):194–203. doi:10.1097/HJH.0b013e32834e1c66.

    CAS  PubMed  Google Scholar 

  33. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–7. doi:10.1016/S0140-6736(07)60108-1. S0140-6736(07)60108-1 [pii].

    Article  CAS  PubMed  Google Scholar 

  34. Cicala S, Devereux RB, de Simone G, Wachtell K, Gerdts E, Boman K, et al. Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study. Am J Hypertens. 2007;20(7):771–6. doi:10.1016/j.amjhyper.2007.01.021. S0895-7061(07)00093-3 [pii].

    Article  PubMed  Google Scholar 

  35. Palmieri V, Okin PM, Bella JN, Wachtell K, Oikarinen L, Gerdts E, et al. Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens. 2006;24(10):2079–84. doi:10.1097/01.hjh.0000244958.85232.06. 00004872-200610000-00025 [pii].

    Article  CAS  PubMed  Google Scholar 

  36. Owada A, Suda S, Hata T, Miyake S. The effects of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. Clin Exp Hypertens. 2001;23(4):305–16.

    Article  CAS  PubMed  Google Scholar 

  37. Volpe M, Tocci G, Pagannone E. Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin-aldosterone system. J Am Soc Nephrol. 2006;17(4 Suppl 2):S36–43. doi:10.1681/ASN.2005121334. 17/4_suppl_2/S36 [pii].

    Article  CAS  PubMed  Google Scholar 

  38. Messerli FH, Michalewicz L. Cardiac effects of combination therapy. Am J Hypertens. 1997;10(7 Pt 2):146S–52. S0895-7061(97)00103-9 [pii].

    Article  CAS  PubMed  Google Scholar 

  39. Messerli FH, Grossman E, Michalewicz L. Combination therapy and target organ protection in hypertension and diabetes mellitus. Am J Hypertens. 1997;10(9 Pt 2):198S–201. S0895706197001532 [pii].

    Article  CAS  PubMed  Google Scholar 

  40. Messerli FH. Combination therapy in hypertension. J Hum Hypertens. 1992;6 Suppl 2:S19–21.

    PubMed  Google Scholar 

  41. Bangalore S, Shahane A, Parkar S, Messerli FH. Compliance and fixed-dose combination therapy. Curr Hypertens Rep. 2007;9(3):184–9.

    Article  CAS  PubMed  Google Scholar 

  42. Ruschitzka FT, Noll G, Luscher TF. Combination of ACE inhibitors and calcium antagonists: a logical approach. J Cardiovasc Pharmacol. 1998;31 Suppl 2:S5–16.

    Article  CAS  PubMed  Google Scholar 

  43. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15)):1547–59. doi:10.1056/NEJMoa0801317. NEJMoa0801317 [pii].

    CAS  PubMed  Google Scholar 

  44. Kang SM, Youn JC, Chae SC, Park CG, Yang JY, Kim MH, et al. Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study. Clin Ther. 2011;33(12):1953–63. doi:10.1016/j.clinthera.2011.11.007.

    Article  CAS  PubMed  Google Scholar 

  45. Kim SH, Ryu KH, Lee NH, Kang JH, Kim WS, Park SW, et al. Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: a randomized, double blind, multicenter study. BMC Res Notes. 2011;4:461. doi:10.1186/1756-0500-4-461.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Waeber B, Ruilope LM. Amlodipine and valsartan as components of a rational and effective fixed-dose combination. Vasc Health Risk Manag. 2009;5(1):165–74.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Plosker GL, Robinson DM. Amlodipine/Valsartan: fixed-dose combination in hypertension. Drugs. 2008;68(3):373–81.

    Article  CAS  PubMed  Google Scholar 

  48. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587-–604. S0149-2918(08)00141-0 [pii].

    Article  CAS  PubMed  Google Scholar 

  49. Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(1):11–25. 2912 [pii].

    Article  CAS  PubMed  Google Scholar 

  50. Weir MR, Hsueh WA, Nesbitt SD, Littlejohn 3rd TJ, Graff A, Shojaee A, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/− hydrochlorothiazide. J Clin Hypertens (Greenwich). 2011;13(6):404–12. doi:10.1111/j.1751-7176.2011.00437.x.

    Article  CAS  Google Scholar 

  51. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252–69. doi:10.1016/j.clinthera.2010.07.008.

    Article  CAS  PubMed  Google Scholar 

  52. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig. 2012;32(10):649–64. doi:10.2165/11636320-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  53. Rozza F, Trimarco V, Izzo R, Santoro M, Manzi MV, Marino M, et al. Antihypertensive response to combination of olmesartan and amlodipine does not depend on method and time of drug administration. High Blood Press Cardiovasc Prev. 2013;20(1):25–32. doi:10.1007/s40292-013-0013-4.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

MV has received research grants from Novartis, has served in international advisory boards of Daiichi Sankyo, Menarini, Malesci, Guidotti and Novartis Farma and has lectured in symposia supported by several drug companies producing ARBs and ACE inhibitors; GT has lectured in symposia supported by Daiichi Sankyo, Menarini, Malesci and Guidotti.

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome “Sapienza”, Sant’Andrea Hospital, Via di Grottarossa 1035-9, Rome, 00189, Italy

    Giuliano Tocci MD, PhD

  2. Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome “Sapienza”, Sant’Andrea Hospital, Via di Grottarossa 1035-9, Rome, 00189, Italy

    Massimo Volpe MD, FAHA, FESC

Authors
  1. Giuliano Tocci MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Massimo Volpe MD, FAHA, FESC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Volpe MD, FAHA, FESC .

Editor information

Editors and Affiliations

  1. Center for Drug Evaluation and Research Division of Cardiovascular and Renal Products, US Food and Drug Administration, Silver Spring, Maryland, USA

    Gowraganahalli Jagadeesh

  2. Pharmacology Unit, AIMST University, Bedong, Malaysia

    Pitchai Balakumar

  3. Center for Drug Evaluation and Research Division of Cardiovascular and Renal Products, US Food and Drug Administration, Silver Spring, Maryland, USA

    Khin Maung-U

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Tocci, G., Volpe, M. (2015). Combination Therapy for the Clinical Management of Hypertension. In: Jagadeesh, G., Balakumar, P., Maung-U, K. (eds) Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Adis, Cham. https://doi.org/10.1007/978-3-319-15961-4_41

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-15961-4_41

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-15960-7

  • Online ISBN: 978-3-319-15961-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation